Hedy Kindler to Programmed Cell Death 1 Receptor
This is a "connection" page, showing publications Hedy Kindler has written about Programmed Cell Death 1 Receptor.
Connection Strength
0.102
-
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023 Nov; 29(11):2814-2824.
Score: 0.053
-
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J Immunother Cancer. 2022 06; 10(6).
Score: 0.048